James Russell Revocable Trust Switches to 13D From 13G on Abeona Therapeutics, Reports 6.1% Stake
James Russell told two Abeona directors the board should consider adding independent directors and said a change in executive leadership should be explored, the filing says.
James Russell Revocable Trust disclosed a 6.1% stake in Abeona Therapeutics Inc., or 3,479,963 shares, and said it no longer holds the stock solely for passive investment purposes, according to a Schedule 13D filed Oct. 23 with the US Securities and Exchange Commission.
The trust previously reported its holding on a Schedule 13G, the filing says. It is filed jointly with James Russell, the trust's sole trustee, who exercises voting and dispositive power over the shares. The filing gives Oct. 15 as the date of the event that required it.
According to the filing, Russell met electronically with two members of Abeona's board: Faith L. Charles, interim chair, and Keith A. Goldan, chair of the audit committee. "At that meeting, Mr. Russell presented a summary of his concerns, including the Board should consider adding additional independent directors, and expressed his view that a change in the Issuer's executive leadership should be explored," the filing says.
On Oct. 15, Charles told Russell the concerns had been shared with the full board, the filing says. It says the reporting persons became concerned about Abeona's operational execution, the consistency of management's public statements with later operating results, and the company's governance.
Depending on the board's response, the reporting persons may propose or seek to nominate director candidates at Abeona's 2027 annual meeting, vote against incumbent directors, communicate with other stockholders or seek board representation, according to the filing.